Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Sequential therapy for patients with primary refractory acute myeloid leukemia - historical prospective analysis of the German and Israeli experience.

Ram R, Scheid C, Amit O, Chemnitz JM, Moshe Y, Hallek M, Wolf D, Avivi I, Holtick U.

Haematologica. 2019 Feb 7. pii: haematol.2018.203869. doi: 10.3324/haematol.2018.203869. [Epub ahead of print]

2.

Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.

Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, Hallek M, Scheid C, Chemnitz JM.

Ann Hematol. 2017 Mar;96(3):479-487. doi: 10.1007/s00277-016-2887-4. Epub 2016 Dec 1.

PMID:
27909887
3.

Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection.

Beyer M, Abdullah Z, Chemnitz JM, Maisel D, Sander J, Lehmann C, Thabet Y, Shinde PV, Schmidleithner L, Köhne M, Trebicka J, Schierwagen R, Hofmann A, Popov A, Lang KS, Oxenius A, Buch T, Kurts C, Heikenwalder M, Fätkenheuer G, Lang PA, Hartmann P, Knolle PA, Schultze JL.

Nat Immunol. 2016 May;17(5):593-603. doi: 10.1038/ni.3399. Epub 2016 Mar 7.

PMID:
26950238
4.

FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission.

Holtick U, Shimabukuro-Vornhagen A, Chakupurakal G, Theurich S, Leitzke S, Burst A, Hallek M, von Bergwelt-Baildon M, Scheid C, Chemnitz JM.

Eur J Haematol. 2016 May;96(5):475-82. doi: 10.1111/ejh.12615. Epub 2015 Aug 25.

PMID:
26132980
5.

[Allogeneic haematopoietic stem cell transplantation - an overview].

Holtick U, Chemnitz JM, Hallek M, Scheid C.

Klin Monbl Augenheilkd. 2015 May;232(5):641-6. doi: 10.1055/s-0035-1545939. Epub 2015 May 19. Review. German.

PMID:
25989032
6.

Meibography and meibomian gland measurements in ocular graft-versus-host disease.

Engel LA, Wittig S, Bock F, Sauerbier L, Scheid C, Holtick U, Chemnitz JM, Hallek M, Cursiefen C, Steven P.

Bone Marrow Transplant. 2015 Jul;50(7):961-7. doi: 10.1038/bmt.2015.72. Epub 2015 Apr 20.

PMID:
25893453
7.

OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation.

Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, Fiedler A, Luznik L, Hellmich M, Wolf D, Hallek M, von Bergwelt-Baildon M, Scheid C.

Eur J Haematol. 2016 Jan;96(1):27-35. doi: 10.1111/ejh.12541. Epub 2015 Mar 16.

8.

Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Shimabukuro-Vornhagen A, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Crit Rev Oncol Hematol. 2015 May;94(2):179-88. doi: 10.1016/j.critrevonc.2014.12.007. Epub 2014 Dec 18. Review.

PMID:
25604498
9.

CD4+ T cell counts reflect the immunosuppressive state of CD4 helper cells in patients after allogeneic stem cell transplantation.

Holtick U, Frenzel LP, Shimabukuro-Vornhagen A, Theurich S, Claasen J, Scheid C, von Bergwelt-Baildon M, Fröhlich H, Wendtner CM, Chemnitz JM.

Ann Hematol. 2015 Jan;94(1):129-37. doi: 10.1007/s00277-014-2166-1. Epub 2014 Aug 15.

PMID:
25118994
10.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2014 Apr 20;(4):CD010189. doi: 10.1002/14651858.CD010189.pub2. Review.

PMID:
24748537
11.

Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.

Chemnitz JM, Chakupurakal G, Bäßler M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Leitzke S, Von Bergwelt-Baildon MS, Scheid C.

ISRN Hematol. 2014 Mar 5;2014:853435. doi: 10.1155/2014/853435. eCollection 2014.

12.

Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.

von Tresckow B, Boell B, Eichenauer D, Beschorner D, Knop S, Goebeler ME, Chemnitz JM, Hallek M, Engert A, Huebel K.

Leuk Lymphoma. 2014 Mar;55(3):695-7. doi: 10.3109/10428194.2013.809074. Epub 2013 Jul 29. No abstract available.

PMID:
23713484
13.

Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.

Theurich S, Fischmann H, Chakupurakal G, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Rothe A, Scheid C, Hallek M, Skoetz N, von Bergwelt-Baildon M.

Crit Rev Oncol Hematol. 2013 Oct;88(1):178-86. doi: 10.1016/j.critrevonc.2013.03.009. Epub 2013 Apr 2. Review.

PMID:
23561334
14.

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Review.

PMID:
22972135
15.

Targeted therapy of soft tissue sarcomas.

Wardelmann E, Chemnitz JM, Wendtner CM.

Onkologie. 2012;35 Suppl 1:21-7. doi: 10.1159/000334958. Epub 2012 Jan 20.

PMID:
22286584
16.

Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4+ T cells.

Theurich S, Malcher J, Becker HJ, Chemnitz JM, Liebig TM, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.

Blood. 2011 Nov 24;118(22):5979-80. doi: 10.1182/blood-2011-05-356683. No abstract available.

17.

Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.

Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C.

Ann Hematol. 2012 Jan;91(1):47-55. doi: 10.1007/s00277-011-1253-9. Epub 2011 May 17.

PMID:
21584670
18.

Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy.

Tuve S, Gayoso J, Scheid C, Radke J, Kiani A, Serrano D, Platzbecker U, Rodríguez-Macías G, Wermke M, Holtick U, Balsalobre P, Middeke JM, Shayegi N, Chemnitz JM, Krause A, Gruner N, Füssel M, Schetelig J, Thiede C, Ehninger G, Hallek M, Díez-Martín JL, Bornhäuser M.

Leukemia. 2011 May;25(5):880-3. doi: 10.1038/leu.2011.11. Epub 2011 Feb 11. No abstract available.

PMID:
21311556
19.

Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.

Chemnitz JM, Uener J, Hallek M, Scheid C.

Ann Hematol. 2010 Oct;89(10):1029-33. doi: 10.1007/s00277-010-0968-3. Epub 2010 Apr 27.

PMID:
20422413
20.

African tick bite fever--papulovesicular exanthem with fever after staying in South Africa.

Schuster J, Tantcheva-Poor I, Wickenhauser C, Chemnitz JM, Hunzelmann N, Krieg T, Hartmann K.

J Dtsch Dermatol Ges. 2008 May;6(5):379-81. Epub 2007 Nov 14. English, German.

PMID:
18021248
21.

Cytomorphologic signs of severe pernicious anemia obscured in a patient with heterozygous hemoglobin Stanleyville II.

Draube A, Chemnitz JM, Wickenhauser C, Staib P, Hallek M, Kreuzer KA.

Eur J Haematol. 2007 Oct;79(4):360-2. Epub 2007 Aug 3.

PMID:
17680815
22.

RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma.

Chemnitz JM, Eggle D, Driesen J, Classen S, Riley JL, Debey-Pascher S, Beyer M, Popov A, Zander T, Schultze JL.

Blood. 2007 Nov 1;110(9):3226-33. Epub 2007 Jul 20.

23.

Human resting CD4+ T cells are constitutively inhibited by TGF beta under steady-state conditions.

Classen S, Zander T, Eggle D, Chemnitz JM, Brors B, Büchmann I, Popov A, Beyer M, Eils R, Debey S, Schultze JL.

J Immunol. 2007 Jun 1;178(11):6931-40.

25.

Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma.

Chemnitz JM, Driesen J, Classen S, Riley JL, Debey S, Beyer M, Popov A, Zander T, Schultze JL.

Cancer Res. 2006 Jan 15;66(2):1114-22.

26.

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.

Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL.

Mol Cell Biol. 2005 Nov;25(21):9543-53.

28.

[Thrombotic thrombocytopenic purpura (Moschkowitz-syndrome) caused by ticlopidine].

Chemnitz JM, Schulz A, Salameh A, Scheid C, Müller R, Draube A, Diehl V, Söhngen D.

Med Klin (Munich). 2000 Feb 15;95(2):96-100. German.

PMID:
10714127

Supplemental Content

Loading ...
Support Center